Close Menu

NEW YORK (GenomeWeb) – HelixBind will receive up to $2 million in funding from public-private partnership CARB-X to develop antibacterial products and rapid diagnostics, the company announced today. 

The funding is for development of a culture-free diagnostic platform called RaPID and the first test to be implemented on the platform, a bloodstream infection (BSI) assay that aims to provide identification of pathogens and drug resistance within hours, directly from blood samples.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.